| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Mutations in the connexin26/GJB2 gene are the most common event in non-syndromic hearing loss among the German population. | Hum Mutat | 2001 | 1.12 |
| 2 | Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. | Ann Oncol | 2006 | 1.10 |
| 3 | Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. | Eur J Cancer | 2008 | 1.03 |
| 4 | Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. | Int J Clin Pharmacol Ther | 2004 | 0.84 |
| 5 | A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors. | Int J Clin Pharmacol Ther | 2003 | 0.77 |
| 6 | [Connexin26 and -30 in the Cochlea and their clinical relevance]. | Laryngorhinootologie | 2001 | 0.76 |